Chemical Abstracts AN 1981:121479, Toth et al., Dec. 1981. |
Andreasen N (1989): The scale for the assessment of negative of symptoms (SANS): conceptual and theoretical foundations. Br J. Psychiatry 155 (suppl. 7):49-52. |
Costa J. Khaled E., Sramek J. Bunney W Jr., Potkin SG (1990): An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Physchopharmacol 10:71-72. |
D'Souza DC, Morrissey K, Abi-Saab D, Damon D, Gil R. Bennett A, Krystal JH (1995): Intravenous glycine and roal D-cycloserine effects on CSF amino acids, plasma hormones, and behavior in healty humans: Implications for Schizophrenia. Schiz Res 15:147, 1995. |
Javitt DC and Zukin Sr (1991): Recent advances in the phencyclidine model of schizopherenia. Am J Psychiatry 148: 1301-1308. |
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994): Amelioration negative symptoms in schizophrenia by glycine. Am J. Psychiatry 151:1234-1236. |
Johnson JW. Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:529-31, 1987. |
Kay SR, Fiszbein A, Opler LA (1987): The positive and negative syndrome scale (PANSS) for schizophrenia. Schiz Bull 13:261-276. |
Leiderman Eduardo, zylberman Ilana, Zukin Stephen R., Cooper Thomas B, Javitt Daniel C. (1996): Preliminary Investigation of High-Dose Oral Glycine on Serum Levels and Negative Symptoms in Schizophrenia: an Open-Label Trial. Biol Psychiatry 39:213-215. |
Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulasekaram B (1992): Glycine in the treatment of schizophrenia-theory and preliminary results, in novel antipsychotic Drugs. Edited by Meltzer HY. New York, Raven Press. |
Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E. Cohen CG, Deutsch SI (1989): glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 12:416-24. |
Waziri R (1989): glycine therapy of schizophrenia. Biol Psychiatry 1988, 23:210-211 �letter!. |
Toth Eugene, Weiss Benjamine, Banay-Schwartz Miriam, Lajtha abel (1986): Effect of Glycine Derivatives on Behavioral changes induced by 3-Mercaptopropionic Acid or Phencyclidine in Mice. 11:1-8. |
Ishimaru M, Kurumaji A, Toru M (1994) Increases in strychnine-insensitive glycine binding sites in cerebral cortex . . . evidence for the glutamate hypothesis, Biol. Psychiatry 35:84-95. |
Kretschmer BD, Schmidt WJ (1992), Glycicne agonists in the treatment of schizophrenia? Clin Neuropharmacol, 15:157-159. |
Olney JW, farber NB (1995) Clutamate receptor dysfunction and schizophrenia, Arch. Gen. Psychiatry, 52:998-1007. |
Rosse RB, Schwartz BL, Davis RE, Deutsch SI (1991), an NMDA intervention strategy in schizophrenia with "low dose" milacemide, Clin Neuropharmacol, 14:268-272. |
Rosse RB, Fay-McCarthy M, Kendrick K. Davis RE, Deutsch SI (1996), D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia, Clin Neuropharmaol, 19:444-50. |
Waziri R (1996), Glycine therapy of schizophrenia: some caveats, Biol Psychiatry, 39:115-6. |
Wood PL (1995): The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo? Life Sci 57:301-10. |
Toth et al. (1982): Elevation of Cerebral Levels of Nonessential Amino Acids in vivo by Administration of Large Doses. Neurochemical Research, 6, (12). |